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OBJECTIVES: To develop a haemophilia-speciﬁc ques-
tionnaire exploring Quality of Life (QoL) of four age
groups: adult (18–36 years), adolescent (12–17 years),
children (7–11 years), and young children (3–7 years).
METHODS: The questionnaire was developed in French
following a literature review and in depth interviews
among 3 men suffering from severe haemophilia, 3
mothers of haemophilia children and 5 clinical experts (2
haematologists, 1 paediatrician, 1 nurse and 1 psycholo-
gist). RESULTS: An adult version of the questionnaire
was ﬁrst developed using patient’s verbatim. It contained
89 questions and covered the following 7 quality of life
domains: Haemophilia and its treatment, Daily life,
School, Professional life, Leisure activities and sports,
Family and friends, Emotional well-being and Future per-
spective. Three other versions of the questionnaire were
developed simultaneously based on the adult version: 77-
item adolescent questionnaire, 22-item children question-
naire and 45-item parent of children questionnaire. All
domains were covered in all versions, except for profes-
sional life. All age-group versions are self-administered
including children from 7 to 11 years old. In addition
parents ﬁll in the 45-item questionnaire for 3–11 age-
groups. Content validity of the questionnaires was sub-
mitted to a Scientiﬁc committee for revision and approval.
The questionnaire is currently being evaluated in a French
cross-sectional pilot study including 54 severe
haemophilia A patients. The objectives are to describe
QoL items among different age groups, assess the accept-
ability and the relevance of the questionnaire and perform
item-reduction. CONCLUSION: The reduced QoL ques-
tionnaire will be available to the scientiﬁc community
soon for further psychometric analysis. The Haemophilia
age-group QoL questionnaire offers the unique opportu-
nity to assess haemophilia patients’ QoL from early child-
hood to adult life. This study was supported by a grant
from Baxter.
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OBJECTIVES: Human growth hormone (hGH) treat-
ment is potentially expensive, and improvements in
dosing accuracy through more precise delivery systems
may lead to reductions in costs due to a minimization of
wastage. To test this hypothesis, we assessed potential
cost savings in the treatment of childhood growth
hormone deﬁciency (GHD) and small for gestational age
(SGA) due to differences in the precision of dosing of
hGH delivery systems. METHODS: Three delivery sys-
tems with differing dose increment size were compared
(Norditropin NordiFlex with dosing increments of 
0.025mg versus Genotropin Pen and Humatrope Pen
both with 0.1mg dosing increments). The recommended
daily dose of hGH for each indication for 1kg body
weight intervals was combined with costs per mg hGH
(taken from published UK sources) to calculate annual
costs of hGH treatment for GHD and SGA patients. The
calculations were based on the assumption that patients
received the required daily dose as a minimum or the
lowest possible injectable dose above the required daily
dose. RESULTS: Due to more precise incremental dose
delivery, using Norditropin NordiFlex versus the two
other comparators was found to save an average of 6.2%
of the annual hGH dose. This translated into annual drug
cost savings of £254.32 and £179.53 per patient com-
pared to Genotropin Pen and Humatrope Pen respec-
tively. In patients with lower body weight, where smaller
dosing increments were more critical to accurate dosing,
even greater savings of up to 10% were found. These
results were robust in all body weight categories and in
both GHD and SGA. CONCLUSIONS: More precise
dosing with the Norditropin NordiFlex delivery system
compared to Genotropin Pen and Humatrope Pen led to
cost savings in the UK setting in patients with GHD and
SGA.
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Generic measures of health-related quality of life
(HrQoL) are designed for use in a wide range of thera-
peutic settings whereas condition-speciﬁc measures have
a much narrower focus. The performance of the latter in
general population settings is largely unknown. OBJEC-
TIVES: 1) To demonstrate the differential health status of
individuals with a speciﬁc condition and hence its health
burden; 2) to test the discriminatory power of a condi-
tion-speciﬁc measure of HrQoL and; 3) to develop nor-
mative reference values of QoL-AGHDA. METHODS:
